KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Tax Provisions (2017 - 2025)

Teva Pharmaceutical Industries' Tax Provisions history spans 9 years, with the latest figure at -$390.0 million for Q4 2025.

  • For the quarter ending Q4 2025, Tax Provisions fell 1492.86% year-over-year to -$390.0 million, compared with a TTM value of -$180.0 million through Dec 2025, down 126.67%, and an annual FY2025 reading of -$180.0 million, down 126.63% over the prior year.
  • Tax Provisions for Q4 2025 was -$390.0 million at Teva Pharmaceutical Industries, down from $214.0 million in the prior quarter.
  • The five-year high for Tax Provisions was $630.0 million in Q2 2024, with the low at -$900.0 million in Q2 2022.
  • Average Tax Provisions over 5 years is $2.9 million, with a median of $34.5 million recorded in 2023.
  • Year-over-year, Tax Provisions surged 4037.5% in 2024 and then plummeted 1492.86% in 2025.
  • Tracing TEVA's Tax Provisions over 5 years: stood at -$24.0 million in 2021, then skyrocketed by 720.83% to $149.0 million in 2022, then crashed by 72.48% to $41.0 million in 2023, then plummeted by 31.71% to $28.0 million in 2024, then plummeted by 1492.86% to -$390.0 million in 2025.
  • Per Business Quant, the three most recent readings for TEVA's Tax Provisions are -$390.0 million (Q4 2025), $214.0 million (Q3 2025), and -$78.0 million (Q2 2025).